EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Filling the void: digoxin and the first randomized evidence in rheumatic heart disease

Viana Copeland, Andrew J.S. Coats, Javed Butler, Stefan D. Anker

Global Cardiology · 03.07.2026 · 4 (2)

DOI: 10.4081/cardio.2026.108 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Global Cardiology, online erschienen am 03.07.2026. Verfasst von Viana Copeland und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The Digoxin in Rheumatic Heart Disease (Dig-RHD) trial marks an important shift in rheumatic heart disease by replacing long-standing therapeutic assumption with direct randomized evidence. In a condition affecting predominantly young patients in low- and middle- income countries, practice has often relied on extrapolation from non-valvular heart failure populations despite clear differences in disease biology, treatment access, and clinical context. By reducing heart failure events in symptomatic patients, Dig-RHD suggests that the value of digoxin in RHD may lie in preventing deterioration and preserving stability, rather than in mortality reduction alone. This distinction matters because worsening heart failure in RHD represents functional decline, recurrent healthcare use, and loss of clinical reserve in settings where advanced interventions may be delayed or unavailable. The findings support reassessment the role of digoxin in symptomatic RHD while underscoring the need to define optimal timing, rhythm-specific effects, disease severity, and background therapy. More broadly, Dig-RHD shows that rigorous outcome trials in RHD are feasible and necessary for a population still underrepresented in cardiovascular research.

Zitieren

APA

Copeland, V., Coats, A. J., Butler, J., & Anker, S. D. (2026). Filling the void: digoxin and the first randomized evidence in rheumatic heart disease. Global Cardiology, 4(2). https://doi.org/10.4081/cardio.2026.108

Vancouver

Copeland V, Coats AJ, Butler J, Anker SD. Filling the void: digoxin and the first randomized evidence in rheumatic heart disease. Global Cardiology. 2026;4(2). doi:10.4081/cardio.2026.108

BibTeX
@article{Copeland2026,
  author = {Copeland, Viana and Coats, Andrew J.S. and Butler, Javed and Anker, Stefan D.},
  title = {Filling the void: digoxin and the first randomized evidence in rheumatic heart disease},
  journal = {Global Cardiology},
  year = {2026},
  volume = {4},
  number = {2},
  doi = {10.4081/cardio.2026.108}
}
Kostenlos starten →